Switching to dapagliflozin (generic) – preferred SGLT2 inhibitor

Switching to dapagliflozin (generic) – preferred SGLT2 inhibitor 

Practices are reminded that dapagliflozin (generic) is the preferred SGLT2 inhibitor across HWE ICB.  Please find linked the updated switch resource document that includes guidance for switching, inclusions, exclusions, a patient letter and some example text message wording to support the switch.  Switching to dapagliflozin will support efficiency savings proposed in the medicines section in the 26/27 ECF.  ScriptSwitch messages are in place to highlight switching opportunities.

A reminder to clinicians on dapagliflozin indications and dosing (refer to the SPC for more information):

·       All patients prescribed Forxiga® (branded dapagliflozin) should be switched to generic dapagliflozin, except those with CKD and without type 2 diabetes.

·       All patients switched from another SGLT2 inhibitor dose should be placed on 10mg dapagliflozin once daily, the recommended standard dose, except those with severe hepatic impairment.

·       No dose adjustment is necessary for patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5mg dapagliflozin is recommended. If well tolerated, the dose can be increased to 10mg.

·       No dose adjustment is required based on renal function.